Trial Profile
A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy HRAIN Biotechnology (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Hrain Biotechnology
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2018 New trial record